MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said its latest fundraising round has brought in £2.09mln before expenses.
In addition, it has secured £256,590 in a separate offer to Australian and UK high-net-worth investors.
The company said the cash injection will be used to advance its drug pipeline, including CannEpil, targeting treatment-resistant epilepsy.
MGC is a specialist in plant-inspired medicines.